Norverapamil: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 22: | Line 22: | ||
{{stub}} | {{stub}} | ||
== Norverapamil == | |||
<gallery> | |||
File:Norverapamil.png|Norverapamil | |||
</gallery> | |||
Latest revision as of 00:47, 17 March 2025
Norverapamil is a pharmacological agent that is the primary metabolite of the calcium channel blocker verapamil. It is used in the treatment of various cardiovascular diseases, including hypertension, angina pectoris, and certain types of arrhythmia.
Pharmacology[edit]
Norverapamil is a phenylalkylamine derivative that acts as a non-selective calcium channel blocker, inhibiting the influx of calcium ions into cardiac muscle and smooth muscle cells. This results in a decrease in intracellular calcium levels, leading to relaxation of the smooth muscle cells in the arteries, and a reduction in blood pressure.
Clinical Use[edit]
Norverapamil is used in the treatment of hypertension, angina pectoris, and certain types of arrhythmia. It is also used off-label for the prevention of migraine headaches. The drug is typically administered orally, and is available in both immediate-release and extended-release formulations.
Side Effects[edit]
Common side effects of norverapamil include dizziness, fatigue, nausea, and constipation. Less common side effects can include bradycardia, hypotension, and edema. In rare cases, norverapamil can cause serious side effects such as heart failure and pulmonary edema.


